Ceftobiprole
- Product NameCeftobiprole
- CAS209467-52-7
- CBNumberCB61509106
- MFC20H22N8O6S2
- MW534.57
- MDL NumberMFCD09954116
- MOL File209467-52-7.mol
- MSDS FileSDS
Chemical Properties
Density | 2.00±0.1 g/cm3(Predicted) |
storage temp. | Store at -20°C,unstable in solution, ready to use. |
solubility | DMSO : 5 mg/mL (9.35 mM) |
pka | 2.46±0.50(Predicted) |
FDA UNII | 5T97333YZK |
Ceftobiprole Price
Product number | Packaging | Price | Product description | Buy |
---|---|---|---|---|
Sigma-Aldrich SML3638 | 5MG | $99 | Ceftobiprole ≥95% (HPLC) |
Buy |
Sigma-Aldrich SML3638 | 25MG | $399 | Ceftobiprole ≥95% (HPLC) |
Buy |
ChemScene CS-0047547 | 5mg | $450 | Ceftobiprole |
Buy |
ChemScene CS-0047547 | 10mg | $750 | Ceftobiprole |
Buy |
ChemScene CS-0047547 | 25mg | $1500 | Ceftobiprole |
Buy |
Ceftobiprole Chemical Properties,Usage,Production
Uses
Broad spectrum antibiotic.Definition
ChEBI: Ceftobiprole is a fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP). It has a role as an antimicrobial agent. It is a cephalosporin and a member of thiadiazoles.Antimicrobial activity
The most important property distinguishing it from older cephalosporins is activity against methicillin-resistant staphylococci, a property conferred by a high affinity for penicillinbinding protein 2′ (2a). MICs for methicillin-resistant strains are nevertheless somewhat higher than those seen with fully susceptible strains. A similar situation exists with coagulasenegative staphylococci and with Str. pneumoniae, for which strains with reduced susceptibility to penicillin are less susceptible than fully resistant strains, while remaining within therapeutically achievable levels.Otherwise activity approximates to that of cephalosporins of group 4 . Activity against Ps. aeruginosa is modest and much reduced against ceftazidime-resistant strains.
Acquired resistance
It is hydrolyzed by extended spectrum β-lactamases of enterobacteria , which are therefore resistant. The prospects for the emergence of resistance during extensive clinical use are presently unclear, though increased resistance in Staph. aureus appears to be difficult to induce under laboratory conditions.Pharmacokinetics
Cmax 500 mg (667 mg prodrug): c. 35 mg/L end infusionintravenous (30-min infusion)
Plasma half-life: c. 3 h
Volume of distribution: 18.4 L
Plasma protein binding: 16%
The prodrug is rapidly hydrolyzed in plasma to release the active form together with diacetyl (2,3-butanediol) and CO2. Distribution approximates to the extracellular fluid volume in adults. There is no accumulation on repeat dosing in subjects with normal renal function.
It is chiefly excreted in urine by glomerular filtration. A urinary concentration exceeding 1 g/L is achieved within the first 2 h of a 500 mg (active drug equivalent) dose and 80–90% of active drug can be recovered within 24 h.
Clinical Use
Ceftobiprole can be used as Broad spectrum antibiotic and in complicated infections of skin and skin structures.Side effects
Limited studies have so far revealed no unexpected side effects. Nausea, vomiting and altered taste sensation appear to be the most common.Preparation Products And Raw materials
Ceftobiprole Supplier
Global(57)Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
+86-0371-86658258 | sales@coreychem.com | China | 29914 | 58 | |
+1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 | |
+86-023-61398051 +8613650506873 |
sales@chemdad.com | China | 39916 | 58 | |
8485655694 | sales@alchempharmtech.com | United States | 63711 | 58 | |
+8619930503252 | daisy@crovellbio.com | China | 5964 | 58 | |
fred.wen@crcorporation.cn | CHINA | 12069 | 58 | ||
+1-5166625404 | Info@alfa-chemistry.com | United States | 21317 | 58 | |
+8618327326525 | masar@topule.com | China | 8474 | 58 | |
+86-852-30606658 | market18@leapchem.com | China | 43348 | 58 | |
+undefined18621343501 | product@acmec-e.com | China | 33349 | 58 |
Related articles
Ceftobiprole: Antimicrobial Activity, Susceptibility, Administration and Dosage, Clinical Uses etc.
Ceftobiprole, formerly BAL9141 or Ro 63-9141, is a novel pyrrolidinone-3-ylidene-methyl cephalosporin with clinically demonstrable activity against methicillin-resistant Staphylococcus aureus (MRSA).
Mar 25,2022
209467-52-7, CeftobiproleRelated Search
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine